Published in Oncogene on February 24, 2005
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet (2010) 3.25
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) (2008) 1.32
WWOX protein expression in normal human tissues. J Mol Histol (2006) 1.22
WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer (2007) 1.13
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
DNA methylation biomarkers: cancer and beyond. Genes (Basel) (2014) 1.11
Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer (2006) 1.05
WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta (2014) 0.98
Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell Death Dis (2014) 0.96
WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma. Cell Death Dis (2013) 0.94
Epigenetics of kidney cancer and bladder cancer. Epigenomics (2011) 0.91
Methylation status of WWOX gene promoter CpG islands in epithelial ovarian cancer and its clinical significance. Biomed Rep (2013) 0.89
Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J Neurooncol (2010) 0.89
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics (2013) 0.88
Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma. Int J Clin Exp Pathol (2010) 0.87
Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch (2010) 0.87
The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol (2008) 0.87
WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study. Tumour Biol (2011) 0.87
Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology (2008) 0.85
Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J Cancer Res Clin Oncol (2009) 0.85
WWOX: a fragile tumor suppressor. Exp Biol Med (Maywood) (2014) 0.84
Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol (2007) 0.84
The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol (2010) 0.83
Functional genetic variant in the Kozak sequence of WW domain-containing oxidoreductase (WWOX) gene is associated with oral cancer risk. Oncotarget (2016) 0.82
Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer. Oncol Lett (2014) 0.82
Epigenetic and genetic alterations affect the WWOX gene in head and neck squamous cell carcinoma. PLoS One (2015) 0.81
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. Cancer Lett (2009) 0.81
A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. Cancer Epidemiol Biomarkers Prev (2012) 0.81
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev (2012) 0.80
A novel approach to simultaneously scan genes at fragile sites. BMC Cancer (2006) 0.79
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells. J Biol Chem (2015) 0.79
Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies. Oncol Lett (2016) 0.79
Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas. Br J Cancer (2009) 0.79
Functions and Epigenetic Regulation of Wwox in Bone Metastasis from Breast Carcinoma: Comparison with Primary Tumors. Int J Mol Sci (2017) 0.78
Multiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer Patients. Int J Breast Cancer (2011) 0.78
WWOX suppresses KLF5 expression and breast cancer cell growth. Chin J Cancer Res (2014) 0.78
The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review. Drug Des Devel Ther (2015) 0.77
Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India. Transl Oncol (2009) 0.77
Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2014) 0.77
HYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer Response. Front Cell Dev Biol (2016) 0.76
The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review. Sci Rep (2016) 0.76
The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review. Drug Des Devel Ther (2016) 0.76
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol (2017) 0.75
The role of WWOX polymorphisms on COPD susceptibility and pulmonary function traits in Chinese: a case-control study and family-based analysis. Sci Rep (2016) 0.75
Functional genetic variant of WW domain-containing oxidoreductase (WWOX) gene is associated with hepatocellular carcinoma risk. PLoS One (2017) 0.75
Maintaining the unmethylated state. Clin Epigenetics (2013) 0.75
Genetic association study identifies a functional CNV in the WWOX gene contributes to the risk of intracranial aneurysms. Oncotarget (2016) 0.75
Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget (2017) 0.75
Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett (2017) 0.75
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A (2012) 2.07
microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A (2010) 1.97
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Loss of WWOX expression in gastric carcinoma. Clin Cancer Res (2004) 1.55
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res (2006) 1.46
A role for the WWOX gene in prostate cancer. Cancer Res (2006) 1.45
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One (2013) 1.43
Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett (2005) 1.42
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res (2006) 1.42
WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res (2003) 1.42
An antimetastatic role for decorin in breast cancer. Am J Pathol (2008) 1.34
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res (2003) 1.32
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res (2005) 1.31
A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem (2003) 1.30
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget (2014) 1.28
Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet (2012) 1.27
Risk of second cancers in patients with colorectal carcinoids. Dis Colon Rectum (2002) 1.26
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A (2014) 1.22
MicroRNA expression profiling of male breast cancer. Breast Cancer Res (2009) 1.22
Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res (2007) 1.22
High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat (2008) 1.22
Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem (2008) 1.22
Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol (2008) 1.21
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol (2014) 1.20
FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol (2002) 1.19
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer (2011) 1.17
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res (2002) 1.17
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol (2010) 1.16
WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol (2010) 1.16
Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem (2003) 1.16
Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis (2012) 1.16
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer (2007) 1.15
Trichoplein/mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition. EMBO Rep (2010) 1.15
Concordant loss of fragile gene expression early in breast cancer development. Pathol Int (2005) 1.15
Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci U S A (2003) 1.14
Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell (2007) 1.13
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol (2010) 1.13
NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science (2008) 1.12
c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res (2006) 1.12
FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther (2002) 1.11
Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res (2005) 1.11
Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci U S A (2004) 1.10
Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci U S A (2003) 1.09
EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet (2010) 1.08
Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol (2009) 1.08
Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol (2005) 1.08
Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res (2013) 1.08
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol (2013) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol (2010) 1.06
Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J (2003) 1.06
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res (2007) 1.05
Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urol (2004) 1.05
Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Natl Acad Sci U S A (2009) 1.04
Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients. Radiology (2002) 1.04
Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci (2009) 1.03
FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol (2002) 1.03
Classical and follicular variant papillary thyroid carcinoma: comparison of clinical, ultrasonographical, cytological, and histopathological features in 444 patients. Endocr Pathol (2011) 1.02
Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor. J Biol Chem (2006) 1.02
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat (2010) 1.01
The FHIT gene product: tumor suppressor and genome "caretaker". Cell Mol Life Sci (2014) 1.01